PDF(Pubmed)
Abstract：
UNASSIGNED: Oure review aimed to examine evidence on the safety and efficacy of direct oral anticoagulants (DOAC) vs Vitamin K antagonists (VKA) in patients with solid organ transplants.
UNASSIGNED: PubMed, Embase, and Web of Science libraries were searched from inception to 25th November 2023 for all studies comparing DOAC with VKA in solid organ recipients.
UNASSIGNED: Nine studies were included with patients who had undergone kidney, heart, or liver transplants. Meta-analysis showed that patients receiving DOAC had a significantly reduced risk of composite bleeding as compared to those with VKA (RR: 0.45 95% CI: 0.30, 0.68 I2=25%). However, the risk of major bleeding was not significantly different between the two groups (RR: 0.76 95% CI: 0.40, 1.42 I2=37%). Pooled analysis showed that the risk of VTE (RR: 0.90 95% CI: 0.72, 1.13 I2=0%) and ischemic stroke (RR: 0.87 95% CI: 0.39, 1.94 I2=12%) was not significantly different between DOAC and VKA groups.
UNASSIGNED: Limited data shows that DOAC are safe and effective in patients with solid organ transplants. The overall risk of bleeding may be reduced with the use of DOAC. There is a need for randomized controlled trials comparing DOAC and VKA in such patients to obtain high-quality evidence.
UNASSIGNED: PubMed, Embase, and Web of Science libraries were searched from inception to 25th November 2023 for all studies comparing DOAC with VKA in solid organ recipients.
UNASSIGNED: Nine studies were included with patients who had undergone kidney, heart, or liver transplants. Meta-analysis showed that patients receiving DOAC had a significantly reduced risk of composite bleeding as compared to those with VKA (RR: 0.45 95% CI: 0.30, 0.68 I2=25%). However, the risk of major bleeding was not significantly different between the two groups (RR: 0.76 95% CI: 0.40, 1.42 I2=37%). Pooled analysis showed that the risk of VTE (RR: 0.90 95% CI: 0.72, 1.13 I2=0%) and ischemic stroke (RR: 0.87 95% CI: 0.39, 1.94 I2=12%) was not significantly different between DOAC and VKA groups.
UNASSIGNED: Limited data shows that DOAC are safe and effective in patients with solid organ transplants. The overall risk of bleeding may be reduced with the use of DOAC. There is a need for randomized controlled trials comparing DOAC and VKA in such patients to obtain high-quality evidence.
摘要：
■Oure综述旨在研究直接口服抗凝剂（DOAC）与维生素K拮抗剂（VKA）在实体器官移植患者中的安全性和有效性的证据。
■PubMed,Embase,从开始到2023年11月25日，我们搜索了WebofScience图书馆，以获取将DOAC与VKA在实体器官接受者中进行比较的所有研究。
■九项研究纳入了接受肾脏治疗的患者，心,或者肝移植.Meta分析显示，与VKA患者相比，接受DOAC的患者复合出血风险明显降低（RR：0.4595％CI：0.30，0.68I2=25％）。然而,两组的大出血风险无显著差异(RR:0.7695%CI:0.40,1.42I2=37%).汇总分析显示，DOAC组和VKA组发生VTE（RR：0.9095%CI：0.72，1.13I2=0%）和缺血性卒中（RR：0.8795%CI：0.39，1.94I2=12%）的风险无显著差异。
■有限的数据表明，DOAC在实体器官移植患者中是安全有效的。使用DOAC可以降低出血的总体风险。需要在此类患者中比较DOAC和VKA的随机对照试验，以获得高质量的证据。
■PubMed,Embase,从开始到2023年11月25日，我们搜索了WebofScience图书馆，以获取将DOAC与VKA在实体器官接受者中进行比较的所有研究。
■九项研究纳入了接受肾脏治疗的患者，心,或者肝移植.Meta分析显示，与VKA患者相比，接受DOAC的患者复合出血风险明显降低（RR：0.4595％CI：0.30，0.68I2=25％）。然而,两组的大出血风险无显著差异(RR:0.7695%CI:0.40,1.42I2=37%).汇总分析显示，DOAC组和VKA组发生VTE（RR：0.9095%CI：0.72，1.13I2=0%）和缺血性卒中（RR：0.8795%CI：0.39，1.94I2=12%）的风险无显著差异。
■有限的数据表明，DOAC在实体器官移植患者中是安全有效的。使用DOAC可以降低出血的总体风险。需要在此类患者中比较DOAC和VKA的随机对照试验，以获得高质量的证据。
